Siegall Clay B
SEC-identified person · CIK 1167496 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Shattuck Labs, Inc. STTK | Director | filed 2024 - 2026 |
| Immunome Inc. IMNM | Director · President and CEO | filed 2023 - 2026 |
| Tourmaline Bio, Inc. TRML | Director | filed 2023 - 2025 |
| Seagen Inc. SGEN | Director · See Remarks | filed 2006 - 2022 |
| Nurix Therapeutics, Inc. NRIX | Director | filed 2021 - 2022 |
| Ultragenyx Pharmaceutical Inc. RARE | Director | filed 2014 - 2020 |
| Alder Biopharmaceuticals INC ALDR | Director | filed 2014 - 2019 |
| Synlogic, INC. SYBX | Director | filed 2015 - 2016 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.